After administration of apaziquone directly into the urinary bladder (intravesically), the drug and its active metabolite were not detected in [[Blood plasma|plasma]], and there were no systemic [[side effect]]s.<ref name=Puri06>{{cite journal |vauthors=Puri R, Palit V, Loadman PM |title=Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer |journal=J. Urol. |volume=176 |issue=4 Pt 1 |pages=1344–8 |date=October 2006 |pmid=16952628 |doi=10.1016/j.juro.2006.06.047 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(06)01426-1|display-authors=etal}}</ref><ref>{{cite journal |vauthors=Hendricksen K, Gleason D, Young JM |title=Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer |journal=J. Urol. |volume=180 |issue=1 |pages=116–20 |date=July 2008 |pmid=18485407 |doi=10.1016/j.juro.2008.03.031 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(08)00591-0|display-authors=etal}}</ref>
